United Therapeutics Corporation
UTHR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $15,948,368 | $10,290,852 | $12,653,095 | $9,701,992 |
| - Cash | $1,697,200 | $1,207,700 | $961,200 | $894,800 |
| + Debt | $300,000 | $700,000 | $800,000 | $800,000 |
| Enterprise Value | $14,551,168 | $9,783,152 | $12,491,895 | $9,607,192 |
| Revenue | $2,877,400 | $2,327,500 | $1,936,300 | $1,685,500 |
| % Growth | 23.6% | 20.2% | 14.9% | – |
| Gross Profit | $2,567,700 | $2,070,000 | $1,789,600 | $1,563,000 |
| % Margin | 89.2% | 88.9% | 92.4% | 92.7% |
| EBITDA | $1,654,400 | $1,386,800 | $1,040,300 | $736,800 |
| % Margin | 57.5% | 59.6% | 53.7% | 43.7% |
| Net Income | $1,195,100 | $984,800 | $727,300 | $475,800 |
| % Margin | 41.5% | 42.3% | 37.6% | 28.2% |
| EPS Diluted | 24.64 | 19.81 | 15 | 10.06 |
| % Growth | 24.4% | 32.1% | 49.1% | – |
| Operating Cash Flow | $1,327,100 | $978,000 | $802,500 | $598,200 |
| Capital Expenditures | -$246,500 | -$230,400 | -$138,800 | -$120,800 |
| Free Cash Flow | $1,080,600 | $747,600 | $663,700 | $477,400 |